CLEC1B Antibody

1. CLEC-2 may have a role in unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma PMID: 27564117
2. CLEC-2 and P2Y12 are required for CpG ODN-induced platelet activation and thrombosis, and might be targeted to prevent adverse events in patients at risk. PMID: 28296036
3. Data (including data from studies using cells from knockout mice) suggest that CLEC2/CLEC2R signaling is dependent on thromboxane A2 generation and is potentiated by co-stimulation with different GNAQ agonists. (CLEC2 = C-type lectin CLEC2; CLEC2R = CLEC2 receptor; GNAQ = guanine nucleotide-binding protein G[q] subunit alpha) PMID: 28705934
4. CLEC2 prevents expression of PI3K subunits, in a SYK-dependent manner, to suppress the invasive activities of gastric cancer cells. PMID: 26855187
5. CLEC-2 regulates Akt and MAPK downstream of PI3K and PKC, leading to phosphorylation and inhibition of GSK3alpha/beta, and enhanced platelet aggregation and secretion. PMID: 25858425
6. Data (including data from studies using recombinant proteins) suggest that a diverse range of ligands activate platelets through activation/phosphorylation of CD36/GPVI (glycoprotein VI) and/or CLEC-2 (C-type lectin-like receptor-2). PMID: 25849538
7. PI3K and Tec family kinases play a crucial role in the regulation of platelet activation and Syk phosphorylation downstream of the CLEC-2 receptor PMID: 25767114
8. fucoidan is a novel CLEC-2 receptor agonist that activates platelets through a SFK-dependent signaling pathway PMID: 23341451
9. Dimerization of two phosphorylated CLEC-2 molecules leads to recruitment of the tyrosine kinase Syk via its tandem SH2 domains and initiation of a downstream signaling cascade PMID: 23264619
10. A differential proteomic analysis of basal and rhodocytin-activated platelets with the aim of providing novel clues on CLEC-2 signaling regulation. PMID: 23053573
11. The glycosylation sites (N120 and N134) are necessary for the surface expression of CLEC-2. PMID: 22740230
12. Shedding of CLEC-2 from the cell surface may reflect increased expression of this membrane protein and serve as a marker of disease activity. PMID: 22736279
13. CLEC-2 is the first member of the C-type lectin family of receptors identified to stimulate platelet aggregation through a tyrosine kinase-dependent pathway. (Review) PMID: 21714702
14. Phosphorylation of CLEC-2 is dependent on lipid rafts, actin polymerization, secondary mediators, and Rac1. PMID: 20154214
15. CLEC-2 activates Syk through dimerization. PMID: 20154219
16. X-ray diffraction analysis of human CLEC-2 PMID: 16511244
17. Framework for understanding the effects of rhodocytin venom binding on CLEC-2 and for understanding the nature of endogenous ligands which will provide a basis for rational design of drugs to block ligand binding. PMID: 17132623
18. Crystal structure of rhodocytin, a ligand for the platelet-activating receptor CLEC2, is reported. PMID: 18583525
19. It is the novel platelet activation receptor. (review) PMID: 19483399
20. CLEC-2 exists as a non-disulfide-linked homodimer which could allow each Syk molecule to interact with two YXXL motifs, one from each CLEC-2 monomer. PMID: 19824697

Show More

Hide All

HGNC: 24356

OMIM: 606783

KEGG: hsa:51266

STRING: 9606.ENSP00000298527

UniGene: Hs.409794